The 2-Minute Rule for Is ABBV-744 effective for hematologic cancers?
In Segment C, members will obtain ABBV-744 and oral navitoclax. In Phase D, participants will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment until finally disease progression or perhaps the members are unable to tolerate the study drugs.Feasible new approaches with the prognosis and treatment of AML. (A) The identification of